查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
生物植入物市场 - COVID-19 的增长、趋势、影响和预测 (2023-2028)
市场调查报告书
商品编码
1272698

生物植入物市场 - COVID-19 的增长、趋势、影响和预测 (2023-2028)

Bio-implants Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 111 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在预测期内，生物植入物市场预计将以 8% 的复合年增长率增长。

COVID-19 大流行不仅对感染 COVID-19 的患者产生了重大影响，而且对其他患者也产生了重大影响，导致植入手术被取消以管理和确保资源，并且许多影响了该国的医疗保健系统因为医院缺乏专家来协助这些手术。 例如，根据美国国家医学图书馆 2021 年 10 月在全球范围内发表的一项研究，普外科住院人数下降了 42.8%。 因此，在 COVID-19 大流行期间外科手术的减少影响了市场的增长。 然而，推迟的手术在全球范围内恢復，推动了大流行后时期的市场增长。 因此，预计在预测期内进行的外科手术和手术数量将推动生物植入物市场的发展。

生物植入物市场的主要驱动因素是慢性病和生活方式疾病负担的增加以及对微创手术的日益偏好。 生物植入物有助于在肥胖、感染和肌肉骨骼疾病等情况下更好地控制和特定药物输送。 例如，生物植入物可向骨骼系统提供独特且特异性的药物输送。 据《骨科外科》2021年1月发表的一篇论文显示，北京社区中年人群腰椎峡部裂总患病率为17.26%（男性15.98%，女性18.80%）。 据说女性60岁以后更容易患腰椎病。 此外，根据英国心臟基金会2022年公布的“UK Factsheet January 2022”，2021年日本将有约760万人患有心臟和循环系统疾病，其中男性约400万人，女性约360万人。心臟和循环系统疾病。 因此，患者中心脏病和循环系统疾病的高患病率导致了对更多植入手术和住院治疗的需求。

此外，预计在预测期内，增加产品发布也将推动市场增长。 2021年2月，美敦力推出了TYRX可吸收抗菌包膜——一种可吸收的一次性抗菌包膜，旨在稳定心臟植入式电子设备或植入式神经刺激器。

因此，预计该市场在预测期内将稳定增长。 然而，生物植入物的高成本和不利的报销政策预计将抑制市场增长。

生物植入物市场趋势

在预测期内，心血管植入物部分预计将占据生物植入物市场的很大份额。

用于心臟修復的生物植入物需要功能性血管生成和神经支配，以便与周围的心肌适当整合。 具有干细胞细胞外囊泡的生物植入物可改善急性心肌梗死后的心臟功能。 推动市场细分增长的主要因素是全球心血管疾病患病率上升。 此外，全球老龄化人口正在显着增加，预计在预测期内将为市场带来更多机会。 例如，根据美国心臟协会2021年发表的一篇文章，美国每年约有4万名儿童接受先天性心臟手术。 心血管疾病患病率的增加，增加了对早期诊断和治疗的需求，预计将在预测期内推动介入心脏病学手术的增长。 它将推动心血管植入物领域的增长。 大多数患者选择心臟手术，但生物植入物可用于治疗多种心血管疾病。

产品发布的增加预计也将在预测期内推动所研究细分市场的增长。 例如，2022 年 5 月，Impulse Dynamics 推出了 Optimizer Smart Mini。 它是一种具有心力衰竭监测功能的可充电电池，可为提供者提供重要的临床见解，以帮助管理心力衰竭患者。

因此，由于上述所有因素，预计所研究的细分市场在预测期内将呈现高增长。

生物植入物市场-IMG1

北美生物植入市场有望显着增长

北美在生物植入市场中占有很大份额，预计在预测期内将呈现类似趋势，不会出现重大波动。 推动市场增长的主要因素是慢性病的日益流行和更好的医疗保健基础设施的存在。 根据美国疾病控制与预防中心 (CDC) 2022 年 7 月更新的数据，冠心病是最常见的心脏病，在美国影响着大约 2010 万 20 岁及以上的成年人。我也患有同样的疾病。 此外，CDC 数据表明，每 40 秒就有一人心脏病发作，美国每年有近 805,000 人心脏病发作。 慢性病患者数量的增加预计将增加对整个生物植入物市场的需求。 因此，由于上述所有因素，预计市场在预测期内将呈现高增长率。

此外，根据医疗保险和医疗补助服务中心的数据，从 2019 年到 2028 年，国家医疗保健支出预计将以 5.4% 的复合年增长率增长，到 2028 年将达到 6.2 万亿美元。. 预计 2019 年至 2028 年全国卫生支出的增长速度将比年均 GDP 快 1.1 个百分点，因此卫生在经济中的份额预计将在 2028 年增长 19.7%。 因此，预计不断增加的医疗成本将为生物植入物创造发展机会并推动市场增长。

增加产品发布预计也将在预测期内推动市场增长。 例如，2022年6月，ZimVie在美国推出了美国食品和药物管理局批准的T3 pro tampered implant和Encode emergence healing Abutment。

因此，预计上述因素将推动该地区预测期内的市场增长。

生物植入物市场-IMG2

生物植入行业概况

生物植入市场本质上是整合的，因为在该市场运营的公司数量很少。 竞争格局分析了具有市场份额的知名国际和本地参与者，包括 Implantate AG、Abbott、Bausch & Lomb Incorporated、BIOTRONIK Inc.、Edwards Lifesciences Corporation、LifeNet Health、MiMedx、Smith & Nephew PLC 和 Zimmer Biomet。

其他福利：

  • Excel 格式的市场预测 (ME) 表
  • 3 个月的分析师支持

内容

第一章介绍

  • 调查假设和市场定义
  • 本次调查的范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

  • 市场概览
  • 市场驱动力
    • 慢性病和生活方式相关疾病的负担增加
    • 越来越喜欢微创手术
  • 市场製约因素
    • 生物植入物的高成本
    • 不利的报销政策
  • 波特五力
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模 - 百万美元）

  • 按生物植入物类型
    • 心血管植入物
    • 脊柱植入物
    • 骨科植入物
    • 种植牙
    • 眼科植入物
    • 其他植入物
  • 按材料
    • 生物材料金属和合金
    • 高分子材料
    • 其他材料
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东和非洲
      • 海湾合作委员会
      • 南非
      • 其他中东和非洲地区
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章竞争格局

  • 公司简介
    • aap Implantate AG
    • Abbott Laboratories
    • Bausch & Lomb Incorporated
    • BIOTRONIK Inc.
    • Edwards Lifesciences Corporation
    • LifeNet Health
    • MiMeDX
    • Smith & Nephew PLC
    • Zimmer Biomet
    • Boston Scientific Corporation
    • Stryker Corporation
    • Endo International Plc

第7章 市场机会将来动向

简介目录
Product Code: 55328

The Bio-implants market is expected to register a CAGR of 8% over the forecast period.

The Covid-19 pandemic had an effect on the country's healthcare systems with significant impacts not only on the patients infected with COVID-19 but on others as well, which resulted in the cancellation of implant surgeries to manage and reserve the resources and many hospitals were facing a shortage of professionals to assist these surgeries. For instance, according to the study published in October 2021, by the National Library of Medicine globally, there has been a 42.8% decrease in general surgery admissions. Thus, the reduction in surgical procedures during the COVID-19 pandemic affected the market's growth. However, the postponed surgeries resumed worldwide, driving the market's growth during the post-pandemic period. Hence, the high number of surgical procedures and operations being performed is expected to boost the development of the bio-implant market during the forecast period.

The bio-implants market is primarily driven by the increasing burden of chronic diseases and lifestyle disorders and the rising preference toward minimally invasive surgeries. Bio-implants help in better management and specific drug delivery in conditions such as obesity, infections, and musculoskeletal disorders. For instance, bio-implants provide a unique and specific drug delivery for the skeletal system. According to an article published by Orthopaedic Surgery in January 2021, the total prevalence of lumbar spondylolisthesis in the middle-aged people of the Beijing community was 17.26% (15.98% in males and 18.80% in females). Women are more likely to suffer from lumbar spondylolisthesis after 60 years old. Furthermore, the "UK Factsheet January 2022" published in 2022 by British Heart Foundation shows that around 7.6 million people live with heart and circulatory diseases, and nearly 4 million males and 3.6 million females live with heart and circulatory diseases in the country in 2021. This highly prevalent heart and circulatory disease among patients generate demand for more implant procedures and hospital admissions.

Additionally, the increasing product launches are expected to drive the growth of the market during the forecast period. In February 2021, Medtronic launched TYRX absorbable Antibacterial Envelope- an absorbable, single-use antibacterial envelope designed to stabilize a cardiac implantable electronic device or implanted neurostimulator.

Hence, the market studied is expected to witness steady growth over the forecast period. However, the high cost of bio-implants and unfavorable reimbursement policies are expected to restrain the growth of the market.

Bio-implants Market Trends

Cardiovascular Implants Segment is Expected to Hold the Large Share in the Bio-Implant Market Over the Forecast Period.

Bioimplants for cardiac repair require functional vascularization and innervation for proper integration with the surrounding myocardium. Bioimplants with extra-cellular vesicles from stem cells improve cardiac function after an acute myocardial heart attack. The primary factor driving the market segment's growth is the rising prevalence of cardiovascular diseases worldwide. Moreover, there is an evident rise in the geriatric population globally, which is expected to create more opportunities for the market over the forecast period. For instance, as per the article published by the American Heart Association in 2021, Approximately 40,000 children undergo congenital heart surgery in the United States each year. Such increasing prevalence of cardiovascular diseases, which led to an increasing need for early diagnosis and treatment, is expected to drive the growth of interventional cardiology procedures during the forecast period. It will drive growth in the cardiovascular implants segment. Most patients opt for heart surgery, and bioimplants can be used to treat various cardiovascular diseases.

Also, the increasing product launches are expected to drive the growth of the studied segment during the forecast period. For instance, in May 2022, Impulse Dynamics launched an optimizer smart mini. It is a rechargeable battery with heart failure monitoring that provides important clinical insights to providers to assist in managing their patients with heart failure.

Thus, owing to all the above-mentioned factors, the studied segment is expected to witness high growth over the forecast period.

Bio-implants Market - IMG1

North America is Expected to show a Significant Growth in the Bio-implants Market

North America is found to hold a significant share of the bio-implants market and is expected to show a similar trend over the forecast period without significant fluctuations. The major factors driving the growth of the market are the increasing prevalence of chronic diseases and the presence of better healthcare infrastructure. The Centers for Disease Control and Prevention (CDC) data updated in July 2022 shows that coronary heart disease is the most common type of heart disease, and approximately 20.1 million adults of age 20 and older have the disease in the United States. Additionally, as per the CDC data, every 40 seconds, someone suffers from a heart attack, and nearly 805,000 people in the United States have a heart attack every year. The rising number of cases of chronic diseases is expected to increase the overall demand in the bio-implants market. Thus, owing to all the above-mentioned factors, the market is expected to witness a high growth rate over the forecast period.

Additionally, as per the Centers for Medicare and Medicaid Services, national health spending was projected to grow at an average annual rate of 5.4% from 2019-2028 and reach USD 6.2 trillion by 2028. As national health expenditure is projected to grow 1.1% points faster than the average yearly GDP over 2019-2028, the health share of the economy is projected to rise by 19.7% in 2028. Thus, the increasing healthcare spending is anticipated to create opportunities for developing bioimplants, thereby propelling market growth.

Also, the increasing product launches are expected to drive the market's growth during the forecast period. For instance, In June 2022, ZimVie launched the United States Food and Drug Administration clearing T3 pro tampered implant and Encode emergence healing Abutment in the United States.

Thus, the above-mentioned factors are expected to drive the market's growth during this region's forecast period.

Bio-implants Market - IMG2

Bio-implants Industry Overview

The bio-implants market is consolidated in nature due to the presence of few companies operating. The competitive landscape includes analyzing a few well-known international and local companies that hold market shares and are famous, including Implantate AG, Abbott, Bausch & Lomb Incorporated, BIOTRONIK Inc., Edwards Lifesciences Corporation, LifeNet Health, MiMedx, Smith & Nephew PLC, and Zimmer Biomet, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Burden of Chronic Diseases and Lifestyle Disorders
    • 4.2.2 Rising Preference toward Minimally Invasive Surgeries
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Bio-implants
    • 4.3.2 Unfavorable Reimbursement Policies
  • 4.4 Porter Five Forces
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Type of Bio-implants
    • 5.1.1 Cardiovascular Implants
    • 5.1.2 Spinal implants
    • 5.1.3 Orthopedic Implants
    • 5.1.4 Dental Implants
    • 5.1.5 Ophthalmic Implants
    • 5.1.6 Other Implants
  • 5.2 By Material
    • 5.2.1 Biomaterial Metal and Alloys
    • 5.2.2 Polymers
    • 5.2.3 Other Materials
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 aap Implantate AG
    • 6.1.2 Abbott Laboratories
    • 6.1.3 Bausch & Lomb Incorporated
    • 6.1.4 BIOTRONIK Inc.
    • 6.1.5 Edwards Lifesciences Corporation
    • 6.1.6 LifeNet Health
    • 6.1.7 MiMeDX
    • 6.1.8 Smith & Nephew PLC
    • 6.1.9 Zimmer Biomet
    • 6.1.10 Boston Scientific Corporation
    • 6.1.11 Stryker Corporation
    • 6.1.12 Endo International Plc

7 MARKET OPPORTUNITIES AND FUTURE TRENDS